ASCO 2024: Advances in NSCLC

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM

Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer

Osimertinib success in locally advanced EGFR-mutated NSCLC

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Adagrasib improves on docetaxel in previously treated NSCLC

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC